bs_bs_banner
12
ANZUP Annual Scientific Meeting
National Speakers Bruce Armstrong AM Bruce Armstrong is internationally recognised for his research into the causes and prevention of cancer. He was instrumental, with Prostate Cancer Foundation and Cancer Council Australia leaders, in initiating development of the draft Australian guidelines for PSA testing and early management of PSA detected prostate cancer. Bruce is an Emeritus Professor at the University of Sydney, a Senior Adviser at the Sax Institute Sydney and Chairman of the Board of the NSW Bureau of Health Information. Bruce was made a Member of the Order of Australia in 1998 for his work in cancer epidemiology and a Fellow of the Australian Academy of Science in 2000.
Paul Anderson Mr Paul Anderson MBBS FRACS. Mr Anderson graduated from the University of Melbourne in 1994. After completing Urology training with the Royal Australasian College of Surgeons in Victoria, he completed a fellowship in pelvic oncology at the University Hospital of Wales in Cardiff, UK. He worked as a Consultant Urological Surgeon at Guy’s Hospital in London before returning to Melbourne in 2008 where he practices in Richmond as well as having appointments at the Royal Melbourne Hospital and Peninsula Health as head of the urology department at Frankston hospital. Mr Anderson’s academic interests include both education and research. He spent two years at the Royal Children’s Hospital in full time research in reconstructive urology. He has held university appointments at the University of Melbourne, Monash University, Stanford University, California and Cardiff University, UK. He is an examiner in Physiology for the Royal Australasian College of Surgeons and is a member of the Academy of Surgical Educators. His current research interest is in the fields of bladder cancer and benign prostatic hyperplasia.
Duncan Colyer Duncan Colyer (BN) is a Senior Research Nurse at Peter MacCallum Cancer Centre. After training in
Western Australia he moved to Oxford, UK in 2007 and commenced a career in Clinical Trials. Returning to Australia in 2010, he has worked at Peter MacCallum Cancer Centre where he is Team Leader of the Head and Neck, Lung, Sarcoma and Urology trials team.
Ian Davis Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He holds honorary appointments with the Ludwig Institute for Cancer Research and Austin Health, and as an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Urology Committee, Skin Cancer Committee and Standing Subcommittee on Research for the Cancer Council Victoria. He is the founder of the COSA Urologic Oncology Group, a member of COSA Board and COSA Council, and is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP). He is chair of the ANZUP Board and of its Scientific Advisory Committee.
Haryana Dhillon Dr Haryana Dhillon, Research Fellow in Cancer Survivorship at the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, University of Sydney. Chair of the Clinical Oncological Society of Australia (COSA) Survivorship Group, a member of COSA Board Committee and Council. With the COSA Survivorship Group Haryana has been leading work developing an Astralian model of survivorship care. Haryana co-leads the survivorship research group with active research project sin physical activity, cognitive function, and supportive care after a cancer diagnosis. She is a chief investigator on a number of projects investigating health literacy, informed decision-making, and patient education. Haryana has made a major
13
National Speakers
contribution to the development of several of Australasia’s Cancer Cooperative Trials Groups in the past and is committed to investigator-initiated research that addresses questions of importance to patients, caregivers, and health professionals.
Regional Cancer Centre. Prior to my current position I held a leadership position at the Peter MacCallum Cancer Centre since 2006 as the Chair/Director of the Uro-Oncology service. I am president elect of the Trans Tasman Radiation Oncology Group. My particular interests are in patient care, multi-disciplinary care and new technology implementation.
Louise Emmett Dr. Louise Emmett BhB, MBChB, FRACP, MD. Deputy Director of Imaging Services, In charge of Nuclear Medicine and PET, Clincal Associate Professor, University of New South Wales, Sydney. Clinical Senior Lecturer, Discipline of Medicine, University of Sydney. A/Prof Louise Emmett is Nuclear medicine physician with a specialty interest in the PET imaging of Prostate Cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty fellowship in Toronto, Canada in 2001. She has a strong interest in research, having completed a Doctorate of Medicine in 2012. She commenced work as Director of PET at St Vincent’s Hospital, Sydney in 2012, and has since initiated radiopharmacy production of both F18 fluoromethyl Choline and Ga68 PSMA on the St Vincent’s campus for evaluation of metastatic prostate cancer. She is currently principal investigator of the PROP’s trial: an international imaging trial evaluating the role of F18 Choline/Ga68PSMA/whole body MRI and MP-MRI in the biochemical recurrence post radical prostatectomy setting in men being considered for salvage prostate radiotherapy.
Farshad Foroudi I am a consultant radiation oncologist with a particular interest in uro-oncology, breast cancer and palliative radiotherapy. I have led the development of image guided and adaptive radiotherapy at the Peter MacCallum Cancer Centre, with our pilot work leading to an Australian and New Zealand trial in bladder cancer. I am the Australia principle investigator for the international RAIDER-B trial. I have been the chief investigator on local, state and national research grants in excess of $4.5 million in the last five years. In 2015, I commenced as Director of Radiation Oncology at Austin Health covering radiation oncology both at the Olivia Newton John Cancer Centre and Ballarat
Mark Frydenberg Professor Mark Frydenberg is a clinical professor in the Department of Surgery, Faculty of Medicine, Monash University; Clinical Chairman, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Faculty of Medicine, Monash University and Chairman, Department of Urology, Monash Health, Melbourne, Victoria, Australia. He is currently the President of the Urological Society of Australia and New Zealand, and was the inaugural chairman, of the Urologic Oncology Special Advisory Group of this organisation. His main research interests are in the area of Urologic Oncology having published greater than 130 papers on clinical, epidemiological and psychooncology/survivorship aspects of all major urological cancers, with approximately 10 million dollars in grant funding in urological cancer research over the last 10 years. This included being the principal investigator for the Victorian Cancer Agency funded CAPTIV collaboration (CAncer of the Prostate Translational research In Victoria). He has previously held board membership of Andrology Australia and was the inaugural chairman, Clinical Institute of Speciality Surgery, Epworth Healthcare. He is on the Executive committee of the World Urologic Oncology Federation, the Australian representative of the Asia-Pacific Society of Uro-Oncology, and is a regular reviewer for multiple major urologic journals, NHMRC and Prostate Cancer UK.
James Kench Prof. James Kench is Director of the Department of Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, a Clinical Professor of the University of Sydney, and the senior Visiting Pathologist at the Kinghorn Cancer Centre/Garvan Institute of Medical Research. He has internationally recognized expertise in prostate cancer pathology and a major research interest in diagnostic and prognostic biomarkers. He has published over 130 peer reviewed journal articles and is a member of key international
14
and Australasian committees relating to prostate cancer, including the International Collaboration on Cancer Reporting (ICCR) Dataset Steering Committee and the International Society of Urological Pathology (ISUP) Council. In addition, Dr Kench co-chairs the ICCR Prostate Cancer Dataset Authoring Committee and chairs the National Structured Pathology Reporting Project.
Mei Krishnasamy Mei Krishnasamy is Executive Director of Cancer Nursing and Allied Health at the Peter MacCallum Cancer Centre Melbourne, and Professor of Cancer Nursing, Translational Research at the University of Melbourne. She is President of Clinical Oncological Society of Australia (COSA) (2014-2016) and Past President of the Cancer Nursing Society of Australia (2013).
Fiona MacLean Dr Fiona Maclean is a urogenital pathologist with over 10 years experience. She works at Douglass Hanly Moir Pathology and has particular interest in renal neoplasia. Fiona has been the convenor of the Urogenital module of the RCPA’s Quality Assurance Program since 2009. She has academic appointments at both Macquarie University Hospital and the University of Notre Dame, Sydney. Her other main interest is sarcoma and orthopaedic pathology, recently being the lead author on two chapters of a key textbook in pathology – Sternberg’s Diagnostic Surgical Pathology. She frequently speaks at conferences both in Australia and overseas.
Villis Marshall AC Villis is Chair of the Australian Commission on Safety and Quality in Health Care, Commissioner for the Health Services Gifts Board, Clinical Professor of Surgery Adelaide University. Previously General Manager of the Royal Adelaide Hospital, Sub Prior of the Order of St John, and Chairman of the Australian Cancer Network for the development of guide lines for the management of advanced prostate cancer. Emeritus Professor Villis Marshall AC is also Past President of the Urological Society of Australia and New Zealand and Chair of Kidney Health Australia. He was also Director of Surgical and Specialty services at the Royal Adelaide Hospital and Director Freemason’s Centre for Men’s Health.
ANZUP Annual Scientific Meeting
Claudia Rutherford Dr Rutherford has an Honours degree in Psychology and a PhD in Health Outcome Assessment. She is a Researcher at the Quality of Life Office at the University of Sydney. She has expertise in the assessment of quality of life and other patient-reported outcomes (PROs), systematic reviews, qualitative research, PRO questionnaire development, and psychometrics. Her current research is investigating PROs and treatment decisionmaking in non-muscle invasive bladder cancer.
Addie Wootten Dr Addie Wootten is a clinical psychologist who specialises in the area of urology. She holds a doctorate in clinical psychology from Monash University and works in the department of urology at The Royal Melbourne Hospital and at Australian Prostate Cancer Research and the Epworth Prostate Centre in a clinical and research capacity. In her clinical role Addie commonly works with patients living with prostate cancer. Her work often focuses on issues such as erectile dysfunction, masculine identity, relationship difficulty, and issues of anxiety and depression. Her research focus is on the health and wellbeing of a range of people living with cancer with particular focus on men with prostate cancer. She has authored a number of peer-reviewed scientific papers and book chapters and is also the principal investigator of a number of research projects funded by the Prostate Cancer Foundation of Australia, beyondblue and the Victorian Cancer Agency.
Xue Qin Yu Dr Xue Qin Yu is a Research Fellow in the Cancer Research Division at Cancer Council NSW. His primary research focus is cancer epidemiology, statistical modelling and health services research. His work includes developing statistical methods to estimate regional variation in cancer survival, and using such estimates to identify cancer types with the greatest potential for improvement in survival through improvements in cancer care. His current area of interest is cancer prevalence, with a focus on the development and application of statistical tools to evaluate the cancer health care system and predict future requirements for cancer care.
12
ANZUP Annual Scientific Meeting
National Speakers Bruce Armstrong AM Bruce Armstrong is internationally recognised for his research into the causes and prevention of cancer. He was instrumental, with Prostate Cancer Foundation and Cancer Council Australia leaders, in initiating development of the draft Australian guidelines for PSA testing and early management of PSA detected prostate cancer. Bruce is an Emeritus Professor at the University of Sydney, a Senior Adviser at the Sax Institute Sydney and Chairman of the Board of the NSW Bureau of Health Information. Bruce was made a Member of the Order of Australia in 1998 for his work in cancer epidemiology and a Fellow of the Australian Academy of Science in 2000.
Paul Anderson Mr Paul Anderson MBBS FRACS. Mr Anderson graduated from the University of Melbourne in 1994. After completing Urology training with the Royal Australasian College of Surgeons in Victoria, he completed a fellowship in pelvic oncology at the University Hospital of Wales in Cardiff, UK. He worked as a Consultant Urological Surgeon at Guy’s Hospital in London before returning to Melbourne in 2008 where he practices in Richmond as well as having appointments at the Royal Melbourne Hospital and Peninsula Health as head of the urology department at Frankston hospital. Mr Anderson’s academic interests include both education and research. He spent two years at the Royal Children’s Hospital in full time research in reconstructive urology. He has held university appointments at the University of Melbourne, Monash University, Stanford University, California and Cardiff University, UK. He is an examiner in Physiology for the Royal Australasian College of Surgeons and is a member of the Academy of Surgical Educators. His current research interest is in the fields of bladder cancer and benign prostatic hyperplasia.
Duncan Colyer Duncan Colyer (BN) is a Senior Research Nurse at Peter MacCallum Cancer Centre. After training in
Western Australia he moved to Oxford, UK in 2007 and commenced a career in Clinical Trials. Returning to Australia in 2010, he has worked at Peter MacCallum Cancer Centre where he is Team Leader of the Head and Neck, Lung, Sarcoma and Urology trials team.
Ian Davis Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He holds honorary appointments with the Ludwig Institute for Cancer Research and Austin Health, and as an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Urology Committee, Skin Cancer Committee and Standing Subcommittee on Research for the Cancer Council Victoria. He is the founder of the COSA Urologic Oncology Group, a member of COSA Board and COSA Council, and is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP). He is chair of the ANZUP Board and of its Scientific Advisory Committee.
Haryana Dhillon Dr Haryana Dhillon, Research Fellow in Cancer Survivorship at the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, University of Sydney. Chair of the Clinical Oncological Society of Australia (COSA) Survivorship Group, a member of COSA Board Committee and Council. With the COSA Survivorship Group Haryana has been leading work developing an Astralian model of survivorship care. Haryana co-leads the survivorship research group with active research project sin physical activity, cognitive function, and supportive care after a cancer diagnosis. She is a chief investigator on a number of projects investigating health literacy, informed decision-making, and patient education. Haryana has made a major
13
National Speakers
contribution to the development of several of Australasia’s Cancer Cooperative Trials Groups in the past and is committed to investigator-initiated research that addresses questions of importance to patients, caregivers, and health professionals.
Regional Cancer Centre. Prior to my current position I held a leadership position at the Peter MacCallum Cancer Centre since 2006 as the Chair/Director of the Uro-Oncology service. I am president elect of the Trans Tasman Radiation Oncology Group. My particular interests are in patient care, multi-disciplinary care and new technology implementation.
Louise Emmett Dr. Louise Emmett BhB, MBChB, FRACP, MD. Deputy Director of Imaging Services, In charge of Nuclear Medicine and PET, Clincal Associate Professor, University of New South Wales, Sydney. Clinical Senior Lecturer, Discipline of Medicine, University of Sydney. A/Prof Louise Emmett is Nuclear medicine physician with a specialty interest in the PET imaging of Prostate Cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty fellowship in Toronto, Canada in 2001. She has a strong interest in research, having completed a Doctorate of Medicine in 2012. She commenced work as Director of PET at St Vincent’s Hospital, Sydney in 2012, and has since initiated radiopharmacy production of both F18 fluoromethyl Choline and Ga68 PSMA on the St Vincent’s campus for evaluation of metastatic prostate cancer. She is currently principal investigator of the PROP’s trial: an international imaging trial evaluating the role of F18 Choline/Ga68PSMA/whole body MRI and MP-MRI in the biochemical recurrence post radical prostatectomy setting in men being considered for salvage prostate radiotherapy.
Farshad Foroudi I am a consultant radiation oncologist with a particular interest in uro-oncology, breast cancer and palliative radiotherapy. I have led the development of image guided and adaptive radiotherapy at the Peter MacCallum Cancer Centre, with our pilot work leading to an Australian and New Zealand trial in bladder cancer. I am the Australia principle investigator for the international RAIDER-B trial. I have been the chief investigator on local, state and national research grants in excess of $4.5 million in the last five years. In 2015, I commenced as Director of Radiation Oncology at Austin Health covering radiation oncology both at the Olivia Newton John Cancer Centre and Ballarat
Mark Frydenberg Professor Mark Frydenberg is a clinical professor in the Department of Surgery, Faculty of Medicine, Monash University; Clinical Chairman, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Faculty of Medicine, Monash University and Chairman, Department of Urology, Monash Health, Melbourne, Victoria, Australia. He is currently the President of the Urological Society of Australia and New Zealand, and was the inaugural chairman, of the Urologic Oncology Special Advisory Group of this organisation. His main research interests are in the area of Urologic Oncology having published greater than 130 papers on clinical, epidemiological and psychooncology/survivorship aspects of all major urological cancers, with approximately 10 million dollars in grant funding in urological cancer research over the last 10 years. This included being the principal investigator for the Victorian Cancer Agency funded CAPTIV collaboration (CAncer of the Prostate Translational research In Victoria). He has previously held board membership of Andrology Australia and was the inaugural chairman, Clinical Institute of Speciality Surgery, Epworth Healthcare. He is on the Executive committee of the World Urologic Oncology Federation, the Australian representative of the Asia-Pacific Society of Uro-Oncology, and is a regular reviewer for multiple major urologic journals, NHMRC and Prostate Cancer UK.
James Kench Prof. James Kench is Director of the Department of Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, a Clinical Professor of the University of Sydney, and the senior Visiting Pathologist at the Kinghorn Cancer Centre/Garvan Institute of Medical Research. He has internationally recognized expertise in prostate cancer pathology and a major research interest in diagnostic and prognostic biomarkers. He has published over 130 peer reviewed journal articles and is a member of key international
14
and Australasian committees relating to prostate cancer, including the International Collaboration on Cancer Reporting (ICCR) Dataset Steering Committee and the International Society of Urological Pathology (ISUP) Council. In addition, Dr Kench co-chairs the ICCR Prostate Cancer Dataset Authoring Committee and chairs the National Structured Pathology Reporting Project.
Mei Krishnasamy Mei Krishnasamy is Executive Director of Cancer Nursing and Allied Health at the Peter MacCallum Cancer Centre Melbourne, and Professor of Cancer Nursing, Translational Research at the University of Melbourne. She is President of Clinical Oncological Society of Australia (COSA) (2014-2016) and Past President of the Cancer Nursing Society of Australia (2013).
Fiona MacLean Dr Fiona Maclean is a urogenital pathologist with over 10 years experience. She works at Douglass Hanly Moir Pathology and has particular interest in renal neoplasia. Fiona has been the convenor of the Urogenital module of the RCPA’s Quality Assurance Program since 2009. She has academic appointments at both Macquarie University Hospital and the University of Notre Dame, Sydney. Her other main interest is sarcoma and orthopaedic pathology, recently being the lead author on two chapters of a key textbook in pathology – Sternberg’s Diagnostic Surgical Pathology. She frequently speaks at conferences both in Australia and overseas.
Villis Marshall AC Villis is Chair of the Australian Commission on Safety and Quality in Health Care, Commissioner for the Health Services Gifts Board, Clinical Professor of Surgery Adelaide University. Previously General Manager of the Royal Adelaide Hospital, Sub Prior of the Order of St John, and Chairman of the Australian Cancer Network for the development of guide lines for the management of advanced prostate cancer. Emeritus Professor Villis Marshall AC is also Past President of the Urological Society of Australia and New Zealand and Chair of Kidney Health Australia. He was also Director of Surgical and Specialty services at the Royal Adelaide Hospital and Director Freemason’s Centre for Men’s Health.
ANZUP Annual Scientific Meeting
Claudia Rutherford Dr Rutherford has an Honours degree in Psychology and a PhD in Health Outcome Assessment. She is a Researcher at the Quality of Life Office at the University of Sydney. She has expertise in the assessment of quality of life and other patient-reported outcomes (PROs), systematic reviews, qualitative research, PRO questionnaire development, and psychometrics. Her current research is investigating PROs and treatment decisionmaking in non-muscle invasive bladder cancer.
Addie Wootten Dr Addie Wootten is a clinical psychologist who specialises in the area of urology. She holds a doctorate in clinical psychology from Monash University and works in the department of urology at The Royal Melbourne Hospital and at Australian Prostate Cancer Research and the Epworth Prostate Centre in a clinical and research capacity. In her clinical role Addie commonly works with patients living with prostate cancer. Her work often focuses on issues such as erectile dysfunction, masculine identity, relationship difficulty, and issues of anxiety and depression. Her research focus is on the health and wellbeing of a range of people living with cancer with particular focus on men with prostate cancer. She has authored a number of peer-reviewed scientific papers and book chapters and is also the principal investigator of a number of research projects funded by the Prostate Cancer Foundation of Australia, beyondblue and the Victorian Cancer Agency.
Xue Qin Yu Dr Xue Qin Yu is a Research Fellow in the Cancer Research Division at Cancer Council NSW. His primary research focus is cancer epidemiology, statistical modelling and health services research. His work includes developing statistical methods to estimate regional variation in cancer survival, and using such estimates to identify cancer types with the greatest potential for improvement in survival through improvements in cancer care. His current area of interest is cancer prevalence, with a focus on the development and application of statistical tools to evaluate the cancer health care system and predict future requirements for cancer care.
